Press release
Efficacy of “Mini IVF” Under Question, New Study at Center for Human Reproduction Reveals
April 4, 2012 (New York, NY) —A new study by New York’s Center for Human Reproduction (CHR) has cast doubts on the efficacy of low intensity IVF (LI-IVF) programs, marketed under various names like “mini IVF” and “natural IVF.” According to the study, LI-IVF programs, which utilize lower doses of fertility medications to reduce costs and monitoring visits, do not live up to their proponents’ claims of pregnancy rates comparable to those in conventional low cost IVF.To evaluate the claims that LI-IVF is more economical and more “patient-friendly,” researchers at CHR matched patients in LI-IVF cycles to comparable patients undergoing traditional IVF cycles. In the resulting study, just published online in the medical journal Reproductive Biomedicine Online1, patients in LI-IVF cycles produced significantly fewer oocytes and embryos, and faced much lower pregnancy rates. Lower pregnancy rates for LI-IVF patients were observed both in initial IVF cycles and cumulatively, taking account of subsequent transfers of cryopreserved embryos.
Most surprisingly, however, when overall costs to achieve a pregnancy were compared, highly touted "cost savings" with LI-IVF were nowhere to be observed. Lower pregnancy rates associated with LI-IVF meant that LI-IVF patients on average needed more cycles to have a take-home baby, which meant the lower per-cycle cost of LI-IVF did not translate into lower cost to achieve a successful pregnancy and delivery. Patients in LI-IVF cycles also took longer to conceive.
“LI-IVF appears to reduce pregnancy chances and prolong time to conception without offering any appreciable compensatory financial benefits,” summarizes Norbert Gleicher, MD, the study’s lead author and medical director of CHR. “When patients started asking for LI-IVF at our center, we, like many other IVF centers, decided to offer the procedure. In contrast to other centers, we, however, explained to our patients that LI-IVF should still be considered ‘experimental’ since no data existed, that compared this method of IVF to standard IVF.”
CHR required that patients sign “experimental” informed consents, and started accumulating outcome data. Dr. Gleicher now notes: “As the result of our study well demonstrates, doing otherwise would have been rather unethical.”
“We must caution patients against resorting to ‘mini IVF’ or ‘natural IVF’ without carefully weighing their options,” warns David Barad, MD, another author of the study and director of clinical ART at CHR. “Until more data becomes available, physicians should offer LI-IVF only as an experimental procedure.”
1Gleicher N et al., A case-control pilot study of low-intensity IVF in good-prognosis patients. Reprod Biomed Online 2012; In press. [Epub ahead of print].
About Center for Human Reproduction
Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com) is a leading fertility center in New York City with a worldwide reputation as a "fertility center of last resort," offering cutting-edge, research-based treatment options to patients with even the most complex cases of infertility. Dr. Gleicher and Dr. Barad are available for additional comments.
Communications Manager
Center for Human Reproduction
212-994-4400
4491
webadmin@thechr.com
21 E. 69th Street
New York, NY 10021
212-994-4499
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Efficacy of “Mini IVF” Under Question, New Study at Center for Human Reproduction Reveals here
News-ID: 217021 • Views: …
More Releases from Center for Human Reproduction

IVF Success Rates Not Improved by Preimplantation Genetic Screening, According t …
There is no evidence that recent technical improvements in preimplantation genetic screening (PGS) improve IVF pregnancy chances, according to a paper just published online in the Journal of Assisted Reproduction and Genetics1. The review, by two fertility specialists from New York’s Center for Human Reproduction (CHR), raises important questions, as this “new” PGS is actively marketed to patients as “proven” and “established” to increase IVF success rates.
In the late ‘90s,…

Research from CHR Offers Hope for Women with Treatment-Resistant Thin Endometriu …
November 15, 2012 (New York, NY) – Direct perfusion of the endometrial cavity with granulocyte colony-stimulating factor (G-CSF) improves the thickness of the endometrial lining in IVF patients with too thin endometrium even after treatments, according to a new study just published online in the medical journal Human Reproduction(1).
In the study, 21 women undergoing in vitro fertilization (IVF) cycles at the Center for Human Reproduction (CHR) in New York City…

FMR1 Gene May Control Women’s Fertility Life Cycle, According to Research
October 23, 2012 (New York, NY) – A new study presented at the Annual Meeting of the American Society for Reproductive Medicine (ASRM) in San Diego, CA, offers further evidence that the fragile X mental retardation 1 gene (FMR1 gene) may play an important role in controlling women’s fertility life cycles.
The study, conducted by researchers from the Center for Human Reproduction (CHR), a leading fertility center in New York…

BRCA1/2 Mutation and FMR1 Gene Study Has Potential Implications for Cancer Scree …
BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria. BRCA1/2-positive embryos will only survive when also carrying a specific FMR1 gene genotype.
In a paper…
More Releases for IVF
IVF Services Market Set for Explosive Growth | Nova IVF, Boston IVF, Monash IVF
HTF MI recently introduced Global IVF Services Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence. Some key players from the complete study are Virtus Health, Monash IVF, Care Fertility, Apollo Hospitals, Boston IVF, CooperSurgical, Genea Biomedx,…
IVF Services Market Moving in the Right Direction: Bangkok IVF center, Fertility …
According to HTF Market Intelligence, the Global IVF Services market to witness a CAGR of 0.098% during the forecast period (2023-2029). The Latest Released IVF Services Market Research assesses the future growth potential of the IVF Services market and provides information and useful statistics on market structure and size.
This report aims to provide market intelligence and strategic insights to help decision-makers make sound investment decisions and identify potential gaps and…
IVF Devices and Consumables Market Size To Reach USD 7.73 Billion, Globally, By …
In vitro fertilization (IVF) is a type of assisted reproductive technology in which the ovum is artificially fertilized in laboratory settings and then implanted into the uterus. IVF is one of the widely used treatments, which assists couples with infertility problems, single mothers, and the LGBT community to procreate. Increase in infertility rate, rise in awareness toward IVF, growth in demand for advanced IVF technologies, and surge in IVF success…
IVF Services Market size is Generating Revenue of $25.6 Billion by 2026 | Fresh …
In vitro fertilization (IVF) is a type of assisted reproductive technology in which the ovum is artificially fertilized in laboratory settings and then implanted into the uterus. IVF is one of the widely used treatments, which assists couples with infertility problems and single mothers & the LGBT community to procreate. Increase in infertility rate, rise in trend of delayed pregnancies, surge in IVF success rate, and upsurge in disposable income…
Growth Dynamics on In Vitro Fertilization Market 2020-2026| Key Players: Monash …
The global in vitro fertilization (IVF) market size is prophesized to reach USD 36.39 billion by 2026, with a CAGR 10.1% by 2026. This is attributable to the increasing cases of infertility among people worldwide. This is more common in males than female partners. The market value was USD 16.89 billion in 2018. IVF is a fertilization process wherein sperm and eggs are retrieved as a sample and are combined…
How In Vitro Fertilization Market Will Dominate In Coming Years? Key Players: Mo …
The global in vitro fertilization (IVF) market size is prophesized to reach USD 36.39 billion by 2026, with a CAGR 10.1% by 2026. This is attributable to the increasing cases of infertility among people worldwide. This is more common in males than female partners. The market value was USD 16.89 billion in 2018. IVF is a fertilization process wherein sperm and eggs are retrieved as a sample and are combined…